What is a reasonable screening tool for a fetus with intrauterine growth restriction (IUGR)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Screening Tool for Intrauterine Growth Restriction

None of the options listed (TORCH screening, urine analysis, or chest x-ray) are reasonable first-line screening tools for a baby with intrauterine growth restriction—the appropriate initial evaluation requires a comprehensive anatomic ultrasound survey followed by umbilical artery Doppler assessment. 1, 2

Why the Listed Options Are Not Appropriate

TORCH Screening

  • TORCH screening is not a routine first-line test for all IUGR cases 1
  • While intrauterine infections can cause IUGR, they represent only one of many potential etiologies (maternal, placental, fetal, and genetic factors all contribute) 3, 4
  • TORCH should be considered selectively based on clinical suspicion or specific ultrasound findings, not as universal screening 5

Urine Analysis and Chest X-Ray

  • Neither urine analysis nor chest x-ray are part of the standard diagnostic workup for IUGR 1, 2
  • These tests do not address the primary concerns in IUGR evaluation: structural anomalies, placental function, or fetal well-being 6, 1

What Should Actually Be Done

Primary Screening Tools

Comprehensive anatomic ultrasound survey is the cornerstone of IUGR evaluation:

  • Identifies structural anomalies present in approximately 10% of IUGR fetuses 1
  • Failure to perform this survey is a common pitfall that leads to missed diagnoses 1

Umbilical artery Doppler assessment is the primary surveillance tool:

  • Significantly reduces perinatal deaths (RR 0.71) 1, 2
  • Guides delivery timing and management decisions 6, 2
  • Recommended by the American College of Obstetricians and Gynecologists as essential for IUGR management 2

Additional Evaluation

Genetic testing with chromosomal microarray analysis should be offered when:

  • Fetal growth restriction is detected with malformations 1
  • Unexplained isolated growth restriction is diagnosed before 32 weeks 1
  • Failing to consider genetic testing is a common pitfall, especially for early-onset IUGR 1

Ongoing Surveillance

Serial ultrasound examinations every 2-4 weeks to monitor:

  • Growth parameters 1
  • Amniotic fluid volume 1
  • Doppler studies of maternal and fetal circulations to differentiate placental dysfunction from other causes 5

References

Guideline

Intrauterine Growth Restriction Evaluation and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Intrauterine Growth Restriction Evaluation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Intrauterine growth restriction - part 1.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2016

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is a reasonable screening tool for a baby with intrauterine growth restriction (IUGR)?
When should a cesarean section be considered for a patient at 38.5 weeks of gestation with intrauterine growth restriction?
What is the management for a fetus with intrauterine growth restriction (IUGR)?
Do I need to refer a patient with a history of Intrauterine Growth Restriction (IUGR) to Maternal-Fetal Medicine (MFM)?
What is Stage 1 Intrauterine Growth Restriction (IUGR)?
What is the recommended antibiotic regimen for a patient with Acinetobacter multi-drug resistance, potentially with impaired renal function and underlying health conditions such as diabetes, heart disease, or lung disease?
Is Macrobid (nitrofurantoin) effective for treating an uncomplicated Escherichia coli (E. coli) urinary tract infection (UTI) in an adult or adolescent female patient?
What are the contraindications for Glucagon-like peptide-1 (GLP-1) receptor agonists in patients with a history of thyroid cancer, pancreatitis, or severe gastrointestinal disease?
How can I prepare for the diplomate exam using Harrison's Principle of Internal Medicine 21st edition?
What's the next step in managing a diabetic patient with cellulitis of the right leg, who showed partial response to oral Augmentin (amoxicillin-clavulanate) with a decrease in C-reactive protein (CRP) from elevated to mildly elevated levels?
What is the relationship between Assigned Protection Factor (APF) and occupational risks in selecting respiratory protection equipment for workers?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.